For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.
Study Type
OBSERVATIONAL
Enrollment
6,777
Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
Unnamed facility
Many Locations, Austria
Unnamed facility
Many Locations, Bahrain
Unnamed facility
Many Locations, China
Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of
Time frame: Documentation at baseline and at at least one follow-up visit. Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).
Evaluation of tolerability and safety of Avalox® in daily practice were investigated.
Time frame: Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).
Patient characteristics in acute bacterial sinusitis
Time frame: Documentation at baseline visit.
History and frequency of sinusitis episodes
Time frame: Documentation at baseline visit.
Diagnostic procedures and therapeutic options chosen by physicians in daily practice
Time frame: Documentation at baseline visit.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Many Locations, Egypt
Unnamed facility
Many Locations, France
Unnamed facility
Many Locations, Germany
Unnamed facility
Many Locations, Indonesia
Unnamed facility
Many Locations, Jordan
Unnamed facility
Many Locations, Kuwait
Unnamed facility
Many Locations, Lebanon
...and 9 more locations